Adverse reactions of rush subcutaneous immunotherapy using standardized house dust mite allergen extract and its prediction model construction and analysis.

Renke Mo, Xiaonan Song, Mo Xian, Wanjun Wang, Xu Shi, Wanyi Fu, Jing Li, Nan Jia

Abstract read

In one paragraph

Article in Asia Pacific allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Renke MoDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Xiaonan SongDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Mo XianDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Wanjun WangDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Xu ShiDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Wanyi FuDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Jing LiDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Nan JiaDepartment of Allergy and Clinical Immunology, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allergic diseases are a growing health concern, with house dust mites being a prevalent allergen linked to various allergies. Rush subcutaneous immunotherapy (RIT) achieves maintenance dose rapidly but carries higher risks than conventional immunotherapy (CIT). The combination of Omalizumab with allergen immunotherapy (AIT) has been shown to improve AIT safety. This study investigates the safety of RIT combined with anti-immunoglobulin E (IgE) pretreatment. Methods: This retrospective analysis compared patients with allergic rhinitis and/or allergic asthma sensitive to dust mites who underwent RIT with anti-IgE pretreatment versus CIT at our facility from July 2022 to January 2024. We collected and analyzed demographic data, adverse events, and baseline metrics including visual analog scale scores, daily medication scores, allergic blood test outcomes, and lung function parameters. Results: Our study enrolled 50 patients in the RIT group and 60 in the CIT group. The RIT group demonstrated superior safety, with significantly fewer local adverse reactions during the up-dosing phase compared with CIT ( Conclusion: RIT combined with anti-IgE pretreatment demonstrated low systemic adverse reaction rates and high safety. A combined visual analogue scale scores (VASs) and maximal mid-expiratory flow at 25%-75% prediction model was more accurate in forecasting systemic reactions than individual factor. Further research is required to determine its clinical utility.

Indexed as

House dust mite all ergensimmunotherapyomalizumabpredictive modelsafety

Identifiers

PMID40718126

DOI10.5415/apallergy.0000000000000181

PMCPMC12289100

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.